Articles from June 2022

Two companies co-founded by UI researchers secure a combined $62M in financing to advance disease therapies

The companies, Carbon Biosciences and hC Bioscience, are based on foundational research by University of Iowa (UI) professors John Engelhardt, Ziying Yan, Chris Ahern, and colleagues at other institutions.

Carbon Biosciences Launches with $38 Million Series A Financing to Advance Novel Gene Therapy Platform and Pipeline

Tuesday, June 21, 2022
Founded in part by University of Iowa gene therapy pioneers John F. Engelhardt, Ph.D. and Ziying Yan, Ph.D., along with Robert M. Kotin, Ph.D. and Longwood Fund, Carbon is expanding the gene therapy toolbox for the treatment of the world’s most devastating and difficult to treat diseases.

Mana Capital Acquisition Corp. and Cardio Diagnostics, Inc. Announce Definitive Business Combination Agreement to Create Publicly Listed Company Set to Transform Cardiovascular Disease Through Epigenetics

Wednesday, June 1, 2022
Cardio Diagnostics, Inc. a UI start-up company and a pioneering precision cardiovascular medicine company, and Mana Capital Acquisition Corp., a special purpose acquisition company, announced that they have entered into a definitive business combination agreement that will result in Cardio Diagnostics becoming a publicly listed company.